Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021)

10 Jan 2022

Abstract excerpt

INTRODUCTION: Tyrosine kinase 2 (TYK2) is a member of the JAK family class of kinases that is responsible for mediating the immune response to IL-12, IL-23, and IFNα. The therapeutic value of targeting this pathway in autoimmune diseases is supported by human genetics and multiple companies are developing small-molecule inhibitors as potential new treatments. AREAS COVERED: This article seeks to give a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Mast cells and histamine
Share to Psoriasis: Treatment and Pathogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35001782
DOI: 10.1080/13543776.2022.2026927

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021)PMID 35001782Read ↗

Tyk2 Targeting in Immune-Mediated Inflammatory DiseasesSemantic proximity Read ↗

Therapeutic potential of tyrosine kinase 2 in autoimmunity.Semantic proximity Read ↗

Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712Semantic proximity Read ↗

A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective InhibitorsSemantic proximity Read ↗

Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunitySemantic proximity Read ↗

JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)Semantic proximity Read ↗

TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen PlanopilarisSemantic proximity Read ↗

TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiationSemantic proximity Read ↗

Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.Semantic proximity Read ↗

Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in miceSemantic proximity Read ↗

Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and diseaseSemantic proximity Read ↗

Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.